Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

被引：0

作者：

Kalincik, T. ^{[1
]}

Jokubaitis, V. ^{[2
]}

Spelman, T. ^{[2
]}

Horakova, D. ^{[3
,4
,5
]}

Havrdova, E. ^{[3
,4
,5
]}

Trojano, M. ^{[6
]}

Lechner-Scott, J. ^{[7
]}

Lugaresi, A. ^{[8
]}

Prat, A. ^{[9
]}

Girard, M. ^{[9
]}

Duquette, P. ^{[9
]}

Grammond, P. ^{[10
]}

Solaro, C. ^{[11
]}

Grand'Maison, F. ^{[12
]}

Hupperts, R. ^{[13
]}

Prevost, J. ^{[14
]}

Sola, P. ^{[15
]}

Ferraro, D. ^{[15
]}

Terzi, M. ^{[16
]}

Butler, E. ^{[17
]}

Slee, M. ^{[18
]}

Kermode, A. ^{[19
]}

Fabis-Pedrini, M. ^{[19
]}

McCombe, P. ^{[20
]}

Barnett, M. ^{[21
]}

Shaw, C. ^{[22
]}

Hodgkinson, S. ^{[23
]}

Butzkueven, H. ^{[2
]}

机构：

[1] Royal Melbourne Hosp, Dept Neurol, CORe, Melbourne, Vic, Australia

[2] Univ Melbourne, Dept Med, Melbourne, Vic, Australia

[3] Gen Univ Hosp, Dept Neurol, Prague, Czech Republic

[4] Gen Univ Hosp, Ctr Clin Neurosci, Prague, Czech Republic

[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[6] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

[7] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia

[8] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy

[9] Hop Notre Dame De Bon Secours, Montreal, PQ, Canada

[10] CISSS Chaudiere Appalache, Levis, PQ, Canada

[11] Osped PA Micone, Genoa, Italy

[12] Neuro Rive Sud, Quebec City, PQ, Canada

[13] Zuyderland Ziekenhuis, Sittard, Netherlands

[14] CSSS St JErUme, St Jerome, PQ, Canada

[15] Univ Modena, Dept Biomed Metab & Neurosci, Modena, Italy

[16] 19 Mayis Univ, Fac Med, Samsun, Turkey

[17] Monash Med Ctr, Melbourne, Vic, Australia

[18] Flinders Univ S Australia, Adelaide, SA, Australia

[19] Univ Western Australia, Perth, WA, Australia

[20] Univ Queensland, Brisbane, Qld, Australia

[21] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[22] Geelong Hosp, Geelong, Vic, Australia

[23] Liverpool Hosp, Sydney, NSW, Australia

来源：

MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷

基金：

加拿大健康研究院;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1138

引用

页码：596 / 597

页数：2

共 50 条

[21] Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Boremalm, M.
Juto, A.
Axelsson, M.
Novakova, L.
Frisell, T.
Svenningsson, A.
Lycke, J.
Piehl, F.
Selzer, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (08) : 1060 - 1067
[22] Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study
Laplaud, D. A.
Barbin, L.
Rousseau, C.
Jousset, N.
Casey, R.
Debouverie, M.
Vukusic, S.
De Seze, J.
Brassat, D.
Wiertlewski, S.
Brochet, B.
Pelletier, J.
Vermersch, P.
Edan, G.
Lebrun-Frenay, C.
Clavelou, P.
Thouvenot, E.
Camdessanche, J. -P.
Tourbah, A.
Stankoff, B.
Al Khedr, A.
Cabre, P.
Papeix, C.
Berger, E.
Heinzlef, O.
Debroucker, T.
Moreau, T.
Gout, O.
Bourre, B.
Creange, A.
Labauge, P.
Magy, L.
Defer, G.
Foucher, Y.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 62 - 63
[23] Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY
Nixon, R.
Eckert, B.
Cutter, G.
Mercier, F.
Francis, G.
Kappos, L.
JOURNAL OF NEUROLOGY, 2012, 259 : S68 - S68
[24] ECONOMIC EVALUATION OF NATALIZUMAB VERSUS FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SWEDEN
Alexopoulos, S. T.
Deniz, B.
Walker, A. R.
Arnold, R.
Bates, D.
VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
[25] Fingolimod/natalizumab withdrawalRebound multiple sclerosis: 2 case reports
Reactions Weekly, 2016, 1623 (1) : 93 - 93
[26] Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Unsal, Mirac Aysen
TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (01) : 50 - 51
[27] Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Chitnis, Tanuja
Arnold, Douglas L.
Banwell, Brenda
Brueck, Wolfgang
Ghezzi, Angelo
Giovannoni, Gavin
Greenberg, Benjamin
Krupp, Lauren
Rostasy, Kevin
Tardieu, Marc
Waubant, Emmanuelle
Wolinsky, Jerry S.
Bar-Or, Amit
Stites, Tracy
Chen, Yu
Putzki, Norman
Merschhemke, Martin
Gaertner, Jutta
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11): : 1017 - 1027
[28] Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Alping, Peter
Askling, Johan
Burman, Joachim
Fink, Katharina
Fogdell-Hahn, Anna
Gunnarsson, Martin
Hillert, Jan
Langer-Gould, Annette
Lycke, Jan
Nilsson, Petra
Salzer, Jonatan
Svenningsson, Anders
Vrethem, Magnus
Olsson, Tomas
Piehl, Fredrik
Frisell, Thomas
ANNALS OF NEUROLOGY, 2020, 87 (05) : 688 - 699
[29] Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved
Bianco, Assunta
Rossini, Paolo Maria
Mirabella, Massimiliano
JAMA NEUROLOGY, 2014, 71 (07) : 924 - 925
[30] Fingolimod/natalizumab withdrawalReactivation of multiple sclerosis: 2 case reports
Reactions Weekly, 2017, 1656 (1) : 221 - 221

← 1 2 3 4 5 →